Century Therapeutics, Inc. Other Nonoperating Expense
Century Therapeutics, Inc. (IPSC) reported Other Nonoperating Expense of $540.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2024-03-14
- Century Therapeutics, Inc. other nonoperating expense for the quarter ending 2023-03-31 was $194.00K, a 38.22% decline year-over-year.
- Century Therapeutics, Inc. other nonoperating expense for the quarter ending 2022-12-31 was $413.00K, a 28.66% increase year-over-year.
- Century Therapeutics, Inc. other nonoperating expense for the quarter ending 2022-09-30 was $373.00K, a 15.84% increase year-over-year.
- Century Therapeutics, Inc. other nonoperating expense for the quarter ending 2022-06-30 was $330.00K, a 3.77% increase year-over-year.
- Century Therapeutics, Inc. other nonoperating expense for fiscal 2023 was $540.00K, a 62.24% decline from fiscal 2022.
- Century Therapeutics, Inc. other nonoperating expense for fiscal 2022 was $1.43M, a 12.16% increase from fiscal 2021.
- Century Therapeutics, Inc. other nonoperating expense for fiscal 2021 was $1.27M, a 234.65% increase from fiscal 2020.
- Century Therapeutics, Inc. other nonoperating expense for fiscal 2020 was $381.00K.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $540.00K 10-K · filed 2024-03-14 | |||
| 2023-03-31 | $194.00K 10-Q · filed 2023-05-11 | $607.00K derived: sum of 2 quarters · filed 2024-03-14 | $980.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.31M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-12-31 | $413.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $786.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.12M derived: sum of 3 quarters · filed 2024-03-14 | $1.43M 10-K · filed 2024-03-14 |
| 2022-09-30 | $373.00K 10-Q · filed 2022-11-10 | $703.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.02M 10-Q · filed 2022-11-10 | $1.34M derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-06-30 | $330.00K 10-Q · filed 2022-08-11 | $644.00K 10-Q · filed 2022-08-11 | $965.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.29M derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-03-31 | $314.00K 10-Q · filed 2022-05-16 | $635.00K derived: sum of 2 quarters · filed 2023-03-16 | $957.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.27M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $643.00K derived: sum of 2 quarters · filed 2023-03-16 | $961.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.27M 10-K · filed 2023-03-16 |
| 2021-09-30 | $322.00K 10-Q · filed 2022-11-10 | $640.00K derived: sum of 2 quarters · filed 2022-11-10 | $954.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $318.00K 10-Q · filed 2022-08-11 | $632.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $314.00K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $381.00K 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |